Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

Shares of Moderna (MRNA) rose 6.2% on Apr 9 after management announced encouraging data from a portion of an early-stage study on mRNA-4157/V940, its investigational individualized neoantigen therapy (INT), in certain patients with head and neck cancer. The INT is being developed in collaboration with Merck (MRK) .This portion of the study evaluated the combination of mRNA-4157 and Merck’s blockbuster immuno-oncology drug Keytruda in patients with human papillomavirus negative (HPV-) head and neck squamous ...